You just read:

Gradalis®, Inc. Announces Dosing of First Patient in Pilot Study Combining Vigil® Engineered Autologous Tumor Cell Immunotherapy and Durvalumab in Advanced Breast Cancer

News provided by

Gradalis, Inc.

Aug 29, 2016, 10:07 ET